Cancer is a disease of genes which are caused due to abnormal growth of cells. These abnormal cells further migrate from the original site to other site through blood and lymph system. Lung cancer is one of the types of cancer formed in tissues of the lungs. Lung cancer is a malignant lung carcinoma characterized by abnormal cell growth in lung tissue. Lung cancer decreases the lung ability to provide oxygen to bloodstream. Some of the major symptoms of lung cancer include body mucus, coughing, shortness of breath, wheezing, appetite loss, weight loss and chest pain. Cigarette smoking is the prominent cause of lung cancer. Pipe and cigar smoking are some other causes of lung cancer.
A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/3840
Lung cancer is treated through surgery, chemotherapy, radiation therapy, immunotherapy and vaccine therapy. The primary lung carcinomas originate from epithelial cells. Non-small cell lung cancer, small cell lung cancer and lung carcinoid tumor are three different types of lung cancer. Non-small cell lung cancer is the most common type of lung cancer and it grows slowly compared to other type of lung cancer. Squamous cell carcinoma, adenocarcinoma and large cell carcinoma are subtypes of non-small cell lung cancer. Small cell lung cancer is also known as oat cell cancer and comprises small cell carcinoma and combined small cell carcinoma. Lung carcinoid tumors are uncommon type of tumor which begins in lungs and are made up of neuroendocrine cells. Some of the drugs used to treat non-small cell lung cancer include avastin, gemzar, taxotere and tarceva.
North America followed by Europe dominates the global lung cancer therapeutics market due to rising incidence of lung cancer and growing aging population. Asia is expected to show high growth rate due to rising awareness for better healthcare. Emerging countries such as India is expected to be the fastest growing market due to increase in lung cancer population.
Development of personalized drugs would support the growth of the global lung cancer therapeutics market. Innovative and safer therapies could develop an opportunity for growth of the global lung cancer therapeutics market. However, harmful side effect caused by chemotherapy and radiation therapy could lead a challenge for the global lung cancer therapeutics market.
To view TOC of this report is available upon request @ http://www.persistencemarketresearch.com/toc/3840
Some of the major companies operating in the global lung cancer therapeutics market are Roche, Eli Lilly and company, Pfizer, Agennix AG and Snaofi-Aventis. Other companies include Daiichi Sankyo, AstraZeneca PLC and GlaxoSmithKline PLC.
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Persistence Market Research
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353